News Mortality and Comorbidity Rates Found Higher in MS Patients, Study Finds Mortality and Comorbidity Rates Found Higher in MS Patients, Study Finds by Patricia Silva, PhD | September 10, 2015 Share this article: Share article via email Copy article link A recently published study in the journal Multiple Sclerosis and Related DisordersĀ found notably higher mortality and comorbidity rates among patients suffering from multiple sclerosis (MS) compared to those without the disease. While past studies have reported similar observations, much remains to be understood about MS patients’ risk of premature mortality and developing comorbidities such as type 1 diabetes and inflammatory bowel diseases. Such findings may have critical implications in how the disease should be managed, monitored, and diagnosed. The study is titled, “Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US department of defense administrative claims database“. The investigators gathered and analyzed patient information from theĀ US Department of Defense (DoD) Military Health System database.Ā Comorbidities and all-cause mortality were analyzed, and causes of death were evaluated through linkage with the National Death Index. Cohorts were compared based on mortality (MRR) and event (ERR) rate ratios. Data analysis revealed that all-cause mortality was 2.9Ā timesĀ higher in the MS cohort compared to theĀ non-MS cohort. The most common causes of death in the MS versus non-MS cohort were infectious diseases, diseases of the nervous, respiratory and circulatory systems and suicide. Comorbidities including sepsis, ischemic stroke, attempted suicide and ulcerative colitis were also found to be higher in the MS versus non-MS cohort. In addition, the rate of cancers was found to be higher among the MS cohort in comparison to the non-MS, including lymphoproliferative disorders and melanoma. However, the authors also noted that because MS tends to negatively affect patients’ socioeconomic status, level of physical activity, and entails immunomodulatory treatments, these may also be major factors in MS patients’ increased mortality and comorbidity rates. These findings underscore the importance of improving multiple sclerosis diagnostics, as earlier detection of the disease would lead to adequate preparation of the patient and his/her family concerning the disease, and a much earlier start of treatment. A new study entitled āEffect of Smoking Cessation on Multiple Sclerosis Prognosisā recently revealed that smoking by patients with multiple sclerosis (MS) postĀ diagnosis accelerates their disease progression course. The study was published in the journalĀ JAMA NeurologyĀ and was led by researchers at the Karolinska Institutet in Sweden. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags comorbidity, mortality, MS
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8